# Tris-CAR-T Cell Therapy for Recurrent Glioblastoma

> **NCT05577091** · PHASE1 · RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **GENETIC:** Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.

## Key facts

- **NCT ID:** NCT05577091
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-30
- **Primary completion:** 2024-11-01
- **Final completion:** 2032-11-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-04-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05577091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05577091, "Tris-CAR-T Cell Therapy for Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05577091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*